
Journal of Medicinal Chemistry p. 3321 - 3332 (1993)
Update date:2022-09-26
Topics:
Daines, Robert A.
Chambers, Pamela A.
Pendrak, Israil
Jakas, Dalia R.
Sarau, Henry M.
et al.
A series of trisubstituted pyridines have been prepared that exhibit in vitro leukotriene B4 (LTB4, 1) receptor antagonist activity.Previous disubstituted pyridines from these labs showed high affinity for the LTB4 receptor but demonstrated agonist activity in functional assays (e.g., 2, Ki = 1 nM).Compound 4, the initial lead compound of this new series, showed only modest affinity by comparison (Ki = 282 nM); however, 4 was a receptor antagonist with no demonstrable agonist activity up to 10 μM.Subsequent modifications of the lipid tail and aryl head group region led to the discovery of aniline 50 (SB 201146).This compound, also free of agonist activity, possesses high affinity for the LTB4 receptor (Ki = 4.7 nM).
View MoreBeijing ZhongDaXinHe Chemical Product Co.,Ltd(expird)
Contact:010-52876516
Address:tongzhoubeiyuan
Contact:18669908765
Address:Zibo City, Shandong Province, P.R.China
WuHan rongfashun BioChemical co., LTD
Contact:02788866139
Address:No.95 LuoYu Road,Wuhan
BrightGene Bio-Medical Technology Co., Ltd.
website:https://en.bright-gene.com/
Contact:+86-512-62551801
Address:Building C25 - C31, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Contact:86-21-50966856
Address:Building 5,300 Chuanzhan Road,Pudong New District,Shanghai
Doi:10.1021/jo00040a064
(1992)Doi:10.1021/ja3113752
(2013)Doi:10.1002/aoc.2952
(2013)Doi:10.1021/jo302549v
(2013)Doi:10.1246/cl.1992.807
(1992)Doi:10.1021/ja00975a029
(1966)